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PHOSPHATIDIC ACID STIMULATES
HAIRGROWTH IN MICE
Through a series of convincing experiments, Takahashi and col-
leagues (p. 448) describe in this issue how phosphatidic acid (PA)
is a potent stimulator of both murine hair epithelial cells in vitro
and hair growth in mice in vivo. PA is a biologically active phos-
pholipid that had previously been shown to stimulate growth of a
variety of di¡erent cell types. The authors ¢rst demonstrated that
PA, when compared to a variety of other phopsholipids, is a po-
tent stimulator of both murine hair epithelial cells and murine
epidermal keratinocytes in vitro. They next showed that topical
application of PA induced signi¢cant hair growth (i.e., anagen
induction) in mice. Interestingly, results with topical PA com-
pared favorably to those obtained with topical minoxidil, which
was used as a positive control for these experiments. Lastly, the
authors revealed how PA may be working to stimulate hair
growth by showing up-regulation of the MAPK signaling path-
way and protection from TGF-b-induced apoptosis in murine
hair epithelial cells treated with PA in vitro. Importantly, this re-
search lays the groundwork for further development of PA as a
potential hair growth stimulant in humans.
HUMAN EPIDERMAL LANGERHANS CELLS PRESENT
LIPIDANTIGENS TO T CELLS
IN THE CONTEXT OF CD1a
The paradigm that Langerhans cells (LC) and other antigen pre-
senting cells present protein-derived peptide antigens toT cells in
the context of MHC class I and II molecules is a basic tenet of
modern immunology. What is less clear, although evidence is
rapidly emerging, is that CD1 molecules, which have structural
features similar to MHC class I molecules, can present lipid anti-
gens to T cells. In this issue, Pena-Cruz and colleagues (p. 517)
clearly showed that human epidermal LC present lipid antigens
(derived from Mycobacterium tuberculosis) to cell lines engineered
to express speci¢cTcell receptors that uniquely recognize and re-
spond to lipid antigens in the context of CD1a. These cell lines
were stimulated only in the presence of both CD1aþ LC and li-
pid extracts of M. tuberculosis. Antibodies directed against CD1a,
but not antibodies directed against MHC class I, blocked this sti-
mulation. An important aspect of this work is that the authors
used human epidermal LC (as opposed to murine LC or human
LC-like dendritic cells derived in vitro) for all their experiments,
something that is not easily done given the technical di⁄culties
in isolating large numbers of these cells to perform meaningful
experiments. This paper provides further evidence that certain
antigen presenting cells, in this case epidermal LC, should be
viewed as capable of ‘‘presenting’’ more than simple protein-
derived peptides, adding an additional layer of complexity in
understanding how we immunologically respond in a world of
diverse pathogens.
EVIDENCE THATgp100, A MELANOCYTE
DIFFERENTIATION ANTIGEN, IS AN AUTOANTIGEN
THAT IS RECOGNIZED BYCD8þ T CELLS IN PATIENTS
WITH ACTIVE VITILIGO
Vitiligo is generally recognized as an autoimmune disease. The
details, however, regarding the contributions of humeral versus
cellular immunity, CD4þ versus CD8þ Tcell reactivity, the spe-
ci¢c type(s) of autoantigens, and the relationship between docu-
mented autoimmune activity ex vivo and clinical disease activity
are unclear. The paper by Mandelcorn-Monson and colleagues in
this issue (p. 550) addresses many of these points, and therefore
contributes greatly to increasing our understanding of vitiligo
pathogenesis. For most experiments, the authors isolated PBMC
from HLA-A2þ patients with active vitiligo, stimulated these
cells with well-de¢ned HLA-A2-binding peptides derived from
melanocyte di¡erentiation antigens (gp100, melanA/MART-1,
and tyrosinase), and then assessed IFN-g secretion by CD8þ cy-
totoxic T lymphocyte (CTL) using ELISPOT. Signi¢cant CTL
reactivity was observed when cells were stimulated with gp100-
derived peptides (comparable to levels induced by common recall
antigens), but not when stimulated by peptides derived from
melanA/MART-1 or tyrosinase. Importantly, anti-gp100 CTL re-
activity correlated with the severity and activity of vitiligo. The
results of this study di¡er from others on this topic, especially in
regard to the relative lack of CTL against melanA/MART-1 and
tyrosinase, but the authors do a good job of discussing possible
explanations for these di¡erences.Thus, if con¢rmed, these results
suggest that interfering with anti-gp100 CTL activity should be
explored as a novel therapeutic strategy in patients with vitiligo.
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